Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and ...
The latest update is out from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ).
35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic ...
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of ...
Relay Therapeutics is a biotech company focused on developing small molecule inhibitors for cancer treatment. Their lead agent, lirafugratinib, is being tested for intrahepatic cholangiocarcinoma and ...
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer Fibroblast growth factor receptor (FGFR ...
Innovent Biologics, a world-class biopharmaceutical company that develops and commercialises high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, ...
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback